Is Abbott Wavering Over Alere?
This article was originally published in Clinica
Executive Summary
A non-committal response from Abbott Labs CEO Miles White about the progress of the company’s proposed acquisition of Alere, which is in the midst of a federal investigation over potentially corrupt sales practices abroad, has raised doubts about the $5.8bn transaction. White’s refusal to reaffirm the diagnostic giant’s commitment to the deal slightly eclipsed the positive financial figures it posted for the first quarter this year.